Application of plasma perfusion in hepatic failure.
To evaluate the efficacy of plasma perfusion as a liver-assistance system, 17 patients with hepatic failure were treated with a total 37 sessions of plasma perfusion and 43 sessions of plasma exchange. For plasma perfusion, Plasma-flo AP-08-H was used as a plasma separator, and the separated plasma was passed through an adsorber, Bespore UPC-III (Jap.Med.Suppl., Hiroshima) or BR 350 (Asahi Med. Co., Tokyo). The mean treated plasma volume was 5.0 liters. The mean proportion of bilirubin removed by routine plasma exchange was 29% with a mean of plasma exchange volume of 2.1 L. In the plasma perfusion with Bespore and BR, the removal rates were 37% and 42%, respectively. The plasma ammonia level decreased by 16% (from 121 to 97 mumol/L) with plasma exchange. Likewise, plasma perfusion decreased the plasma ammonia level from 75 to 56 mumol/L with an average decrement rate of 23%. The capacity for removal of amino acids was analyzed in terms of the change in the Fisher score ([Val+Leu+Ileu]/[Tyr+Phe]). The Fisher score was improved by plasma perfusion from 1.8 to 2.4. Thus, we concluded that in terms of removal of bilirubin, ammonia and amino acids, plasma perfusion was as efficient a therapy as plasma exchange. However, further clinical evaluation will be required before this procedure can be applied for the treatment of hepatic failure.
Tabei
K
K
Division of Nephrology, Jichi Medical School, Tochigi, Japan.
Akai
Y
Y
Takeda
S
S
Homma
S
S
Kusano
E
E
Asano
Y
Y
D000328:Adult; D000368:Aged; D000596:Amino Acids / Q000302:isolation & purification; D000641:Ammonia / Q000302:isolation & purification; D001663:Bilirubin / Q000302:isolation & purification; D002648:Child; D002908:Chronic Disease; D005260:Female; D006464:Hemoperfusion / Q000379:methods*; D006801:Humans; D008107:Liver Diseases / Q000097:blood / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010949:Plasma; D010951:Plasma Exchange
D000596:Amino Acids; D000641:Ammonia; D001663:Bilirubin